Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2006-06-28
2010-12-14
McIntosh, III, Traviss C (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S042000, C514S043000, C514S045000, C514S046000, C514S049000, C514S050000, C514S051000
Reexamination Certificate
active
07851456
ABSTRACT:
This invention is directed to a method of enhancing or facilitating the clearance of the lung mucus secretions in a subject. This invention is also directed to a method of facilitating the hydration of the lung mucus secretions in a subject. This invention is further directed to a method of preventing or treating diseases or conditions associated with impaired lung or airway function in a human or other mammal. The method comprises administering to a subject a pharmaceutical composition comprising a therapeutic effective amount of P2Y6receptor agonist compound, wherein said amount is effective to activate the P2Y6receptors on the luminal surface of lung epithelia. The P2Y6receptor agonist compounds useful for this invention include mononucleoside 5′-diphosphates, dinucleoside monophosphate, dinucleoside diphosphates, or dinucleoside triphosphates of general Formula I, or salts, solvates, hydrates thereof.
REFERENCES:
patent: 5292498 (1994-03-01), Boucher
patent: 5635160 (1997-06-01), Boucher, Jr. et al.
patent: 5763447 (1998-06-01), Jacobus et al.
patent: 5837861 (1998-11-01), Pendergast et al.
patent: 5935555 (1999-08-01), Stutts et al.
patent: 6022527 (2000-02-01), Boucher, Jr. et al.
patent: 6143279 (2000-11-01), Boucher et al.
patent: 6159952 (2000-12-01), Shaffer et al.
patent: 6235266 (2001-05-01), Stutts et al.
patent: 6323187 (2001-11-01), Yerxa et al.
patent: 6331529 (2001-12-01), Yerxa et al.
patent: 6348589 (2002-02-01), Pendergast et al.
patent: 6420347 (2002-07-01), Jacobus et al.
patent: 6555675 (2003-04-01), Rideout et al.
patent: 6624150 (2003-09-01), Yerxa et al.
patent: 7132408 (2006-11-01), Boyer et al.
patent: 7435724 (2008-10-01), Douglass et al.
patent: WO 9819685 (1998-05-01), None
patent: WO 9834942 (1998-08-01), None
patent: PCT/US2006/026010 (2007-01-01), None
Byrn et al. Solid-State Chemistry of Drugs, 2d, Chapter 11 Hydrates and Solvates, 233-247, 233.
Morissette et al. Adv. Drug Delivery Rev. 2004, 56, 275-300.
Kellerman, “P2Y2Receptor Agonists, A New Class of Medication Targeted at Improved Mucociliary Clearance,”Chest.121:201S-205S (2002).
Knowles, “Mucous clearance as a primary innate defense mechanism for mammalian airways,”J Clin Invest.109:571-7 (2002).
Kunzelmann & Mall, “Pharmacotherapy of the Ion Transport Defect in Cystic Fibrosis,”Clin Exp Pharmacol Physiol.28:857-67 (2001).
Leipziger, “Control of epithelial transport via luminal P2 receptors,”Am J Physiol Renal Physiol.284: F419-32 (2003).
Schreiber & Kunzelmann, “Purinergic P2Y6Receptors Induce Ca2+and CFTR Dependent CI' Secretion in Mouse Trachea,”Cell Physiol Biochem16: 99-108 (2005).
Schwiebert & Zsembery, “Extracellular ATP as a signaling molecule for epithelial cells,”Biochim Biophys Acta.1615:7-32 (2003).
Korcok, J. et al., “P2Y6 nucleotide receptors activate NF-kappaB and increase survival of osteoclasts”,The Journal of Biological Chemistry,280:17, 16909-16915, (Apr. 29, 2005), XP007909015 abstract; ISSN: 0021-9258.
Schreiber, Rainer et al., “Purinergic P2Y6 receptors induce Ca2+ and CFTR dependent CI- secretion in mouse trachea.”Cellular Physiology&Biochemistry: Int'l Journal of Experimental Cellular Physiology, Biochemistry,&Pharmacology16:1-3, p. 99-108 (2005) XP007909014 abstract; ISSN: 1015-8987.
Supplementary European Search Report for EP 06774477, mailed Sep. 11, 2009.
Boyer José L.
Douglass, III James G.
Redick Catherine C.
Shaver Sammy R.
Howrey LLP
Inspire Pharmaceuticals Inc.
Kung Viola T.
McIntosh, III Traviss C
LandOfFree
P2Y6 receptor agonists for treating lung diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with P2Y6 receptor agonists for treating lung diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and P2Y6 receptor agonists for treating lung diseases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4215712